Associated tags: Genetics, Patient, Histology, MDM2, RAD52, Therapy, Cancer, Pharmaceutical industry, RAIN, Security (finance), Liposarcoma, LPS, Food, Merkel-cell carcinoma, Conference, Webcast, Safety
Locations: RAIN
Retrieved on:
Thursday, October 7, 2021
Private Securities Litigation Reform Act,
MDM2,
Neoplasm,
ER,
Therapy,
Histology,
Conference,
Poster,
Liposarcoma,
Food,
RAIN,
GLOBE,
Genetics,
Cancer,
Merkel-cell carcinoma,
GATA3,
Nasdaq,
U.S. Securities and Exchange Commission,
MCC,
TP53,
Security (finance),
AACR,
PUMA,
Breast,
Gene,
RAD52,
Patient,
LPS,
Pharmaceutical industry,
Risk management,
Vaccine NEWARK, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced data on its oral mouse double minute 2 (MDM2) inhibitor, milademetan, presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held virtually October 7-10, 2021.
Key Points:
- NEWARK, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced data on its oral mouse double minute 2 (MDM2) inhibitor, milademetan, presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held virtually October 7-10, 2021.
- Robust induction of p53 target genes including MIC-1, p21 and PUMA was observed following milademetan treatment indicating re-activation of p53 by milademetan.
- MCC has low rates of p53 mutation and MDM2 dependence in MCC is driven by polyoma virus-induced MDM2 expression in the majority of cases.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
ER,
Therapy,
Nasdaq,
Harvard Medical School,
MCC,
Cancer,
MA,
Hospital,
RAIN,
Conference,
RAD52,
Patient,
Poster,
AACR,
Merkel-cell carcinoma,
Mace Head Atmospheric Research Station,
CA,
Histology,
Genetics,
MDM2,
Research,
Cone Health Women's Hospital,
Breast cancer,
GLOBE,
Pharmaceutical industry,
Management NEWARK, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NEWARK, Calif., October 1, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, and the importance of MDM2 as a therapeutic target at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.
Key Points:
- NEWARK, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NEWARK, Calif., October 1, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, and the importance of MDM2 as a therapeutic target at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.
- This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology.
- Rains lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Retrieved on:
Wednesday, September 22, 2021
GLOBE,
Conference,
RAIN,
Therapy,
Cancer,
Nasdaq,
RAD52,
Patient,
Histology,
Genetics,
MDM2,
Pharmaceutical industry NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.
Key Points:
- NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.
- Additional details can be found below:
A replay of the presentation will be available by visiting the " Events & Presentations " section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
- Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Retrieved on:
Thursday, September 9, 2021
NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
Key Points:
- NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
- Additional details can be found below:
A replay of the presentation will be available by visiting the " Events & Presentations " section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
- Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Retrieved on:
Wednesday, September 1, 2021
Cancer,
RAD52,
Therapy,
Poster,
MDM2,
GLOBE,
Lung cancer,
Patient,
Citigroup,
Conference,
Genetics,
RAIN,
Nasdaq,
Histology,
Pharmaceutical industry NEWARK, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will be presenting a poster at the virtual IASLC 2021 World Conference on Lung Cancer (#WCLC21) being held September 8-14, 2021.
Key Points:
- NEWARK, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will be presenting a poster at the virtual IASLC 2021 World Conference on Lung Cancer (#WCLC21) being held September 8-14, 2021.
- Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will also participate in a Targeted Oncology Panel Discussion at the Citi 16th Annual Biopharma Conference being held September 8-10, 2021.
- Rains lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Well,
Private Securities Litigation Reform Act,
Extremities,
Caris,
MANTRA,
Patient,
Network,
COVID-19,
Research,
Intelligence,
RAIN,
Program,
Cancer,
U.S. Securities and Exchange Commission,
Progression-free survival,
TIME,
Investment,
Safety,
Review,
Histology,
DD,
Incidence,
Trabectedin,
WD,
Webcast,
GLOBE,
Therapy,
Partnership,
Tempus,
Company,
Nasdaq,
RAD52,
Lung cancer,
G&A,
MDM2,
Security (finance),
LPS,
Genetics,
Conference,
Medical device,
Pharmaceutical industry,
Lithium,
Cryptocurrency NEWARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN),. (“Rain”), a late-stage company developing precision oncology therapeutics, today reports financial results for the second quarter and six months ended June 30, 2021, along with an update on the company's key developments, business operations and upcoming milestones.
Key Points:
- (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the second quarter and six months ended June 30, 2021, along with an update on the company's key developments, business operations and upcoming milestones.
- Rain has made strong progress in the second quarter and six months ended 2021, said Avanish Vellanki, co-founder and chief executive officer of Rain.
- Rain anticipates enrolling the first patient in its basket study of patients with MDM2-amplified advanced solid tumors (MANTRA-2) in the second half of 2021.
- Presentations for milademetan have been submitted and accepted to the 2021 World Conference of Lung Cancer (Sept. 8-14, 2021) and the 2021 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics virtual conference (Oct. 7-10, 2021).
NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.
Key Points:
- NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.
- On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m.
- Rains lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
- In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Approximately 160 patients are expected to be randomized in a 1:1 ratio to receive milademetan or trabectedin.
Key Points:
- Approximately 160 patients are expected to be randomized in a 1:1 ratio to receive milademetan or trabectedin.
- The primary objective of the trial is to compare progression-free survival (PFS) by blinded independent review between the milademetan treatment arm and the trabectedin control arm.
- Secondary endpoints include overall survival, PFS by investigator assessment, objective response rate, duration of response, disease control rate, safety and patient reported outcomes.
- As of July 1, 2021, three WD/DD LPS patients received therapy with milademetan monotherapy for greater than 51 months.
NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announceda master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus genomic analysis platform.
Key Points:
- NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announceda master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus genomic analysis platform.
- We are excited to enhance our tumor agnostic, MDM2-amplified basket trial strategy through this collaboration with Tempus, a company that shares our patient-centric mission, said Robert Doebele, M.D., Ph.D., cofounder and chief scientific officer at Rain Therapeutics.
- We look forward to collaborating with Rain Therapeutics on their exciting Phase 2 asset, RAIN-32, and making this trial option available to patients facing MDM2-amplified cancer.
- In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.For more information, visit www.rainthera.com .
NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, today announceda patient referral partnership with Caris Life Sciences (Caris).
Key Points:
- NEWARK, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, today announceda patient referral partnership with Caris Life Sciences (Caris).
- Rain in-licensed RAIN-32 in September 2020 based on the results of a Phase 1 clinical trial, which demonstrated meaningful antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors.
- Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process.
- We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
